Iradimed Net Income Over Time
| IRMD Stock | USD 99.67 3.41 3.31% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Iradimed Performance and Iradimed Correlation. Will Health Care Equipment & Supplies sector continue expanding? Could Iradimed diversify its offerings? Factors like these will boost the valuation of Iradimed. Market participants price Iradimed higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Iradimed data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 0.247 | Earnings Share 1.75 | Revenue Per Share | Quarterly Revenue Growth 0.17 | Return On Assets |
Iradimed's market price often diverges from its book value, the accounting figure shown on Iradimed's balance sheet. Smart investors calculate Iradimed's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Iradimed's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between Iradimed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Iradimed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Iradimed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Income Analysis
Compare Iradimed and related stocks such as InMode, Axogen Inc, and Tandem Diabetes Care Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| INMD | 336 K | 336 K | 336 K | 336 K | 336 K | 336 K | 336 K | 8.8 M | 22.4 M | 61.1 M | 75 M | 165 M | 161.5 M | 197.9 M | 181.3 M | 93.8 M | 106.4 M |
| AXGN | 500 K | (9.2 M) | (9.4 M) | (14.6 M) | (17.7 M) | (13.4 M) | (14.4 M) | (10.4 M) | (22.4 M) | (29.1 M) | (23.8 M) | (27 M) | (28.9 M) | (21.7 M) | (10 M) | (9 M) | (9.4 M) |
| TNDM | (25.5 M) | (25.5 M) | (33 M) | (63.1 M) | (79.5 M) | (72.4 M) | (83.4 M) | (73 M) | (122.6 M) | (24.8 M) | (34.4 M) | 15.6 M | (94.6 M) | (222.6 M) | (96 M) | (86.4 M) | (90.7 M) |
| AHCO | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (690) | 2.1 M | (21.3 M) | (161.6 M) | 156.2 M | 69.3 M | (678.9 M) | 90.4 M | 81.4 M | 85.4 M |
| IART | (25.4 M) | 28 M | 41.2 M | (17 M) | 34 M | (3.5 M) | 74.6 M | 64.7 M | 60.8 M | 50.2 M | 133.9 M | 169.1 M | 180.6 M | 67.7 M | (6.9 M) | (8 M) | (7.6 M) |
| CTEV | 36.2 M | 36.2 M | 36.2 M | 36.2 M | 36.2 M | 36.2 M | 36.2 M | 36.2 M | 36.2 M | 9.7 M | (520.6 M) | 102.1 M | (572.9 M) | (91.7 M) | (1.6 B) | (1.5 B) | (1.4 B) |
| OPK | (2.7 M) | (1.3 M) | (29 M) | (114.4 M) | (171.7 M) | (30 M) | (48.4 M) | (305.2 M) | (153 M) | (314.9 M) | 30.6 M | (30.1 M) | (328.4 M) | (188.9 M) | (53.2 M) | (47.9 M) | (50.3 M) |
| GDRX | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | 8.8 M | 43.8 M | 66 M | (293.6 M) | (25.3 M) | (32.8 M) | (8.9 M) | 16.4 M | 14.8 M | 15.5 M |
| CRON | (619.5 K) | (619.5 K) | (619.5 K) | (619.5 K) | (4.2 M) | 278.3 K | (885 K) | (1.5 M) | (21.6 M) | 1.2 B | (73.1 M) | (396.1 M) | (168.7 M) | (74 M) | 41.1 M | 37 M | 31.1 M |
| MDXG | (16.7 K) | (10.2 M) | (7.7 M) | (4.1 M) | 6.2 M | 29.4 M | 12 M | 64.7 M | (30 M) | (30 M) | (49.3 M) | (12.3 M) | (30.2 M) | 67.4 M | 42.4 M | 48.8 M | 51.2 M |
Iradimed and related stocks such as InMode, Axogen Inc, and Tandem Diabetes Care Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Iradimed financial statement analysis. It represents the amount of money remaining after all of Iradimed Co operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Iradimed Co | IRMD |
Specialization | Health Care, Health Care Equipment & Services |
| Business Address | 12705 Ingenuity Drive, |
| Exchange | NASDAQ Exchange |
USD 99.67
Check out Iradimed Performance and Iradimed Correlation. You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Iradimed technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.